INTRODUCTION
============

Regulation of glucose disposal by skeletal muscle and exercise
--------------------------------------------------------------

There are globally more than 1 billion overweight adults, at least 300 million of whom are obese. The key causes of obesity are: 1) increased consumption of foods rich in saturated fats and sugars, and 2) the lack of physical activity, which leads to a rise in blood circulating free fatty acids (FFAs). A chronic elevation of circulating FFA leads to a metabolic syndrome, which is a cluster of risk factors such as insulin resistance, hypertension, and dyslipidaemia ([Fig. 1](#F1){ref-type="fig"}). Insulin resistance can be described as the inability of skeletal muscle to switch from fat to carbohydrate (CHO) oxidation in response to a diet-mediated increase in CHO or insulin availability.

The main function of skeletal muscle in vertebrates is the motor function. It is known that when muscle contracts (exercise) to produce force it also increases pyruvate generation by enhancing muscle glycogen degradation and leg glucose uptake from the circulating blood. Pyruvate can either be reduced to lactate or oxidised by pyruvate dehydrogenase complex (PDC) in mitochondria to produce acetyl-CoA according to the following irreversible reaction: pyruvate+coenzyme A (CoASH)+ nicotinamide adenine dinucleotide (NAD^+^)→ acetyl-CoA+ nicotinamide adenine dinucleotide hydrogen (NADH)+CO~2~. Through this reaction and its ability to increase the volume of glucose oxidised in response to exercise and insulin stimulus, skeletal muscle PDC activity (PDCa) plays an important role in the whole body glucose homeostasis.

While 10% of the O~2~ from the blood circulatory system is supplied to skeletal muscle at rest, this value can increase to 80% during strenuous exercise to support the oxidative energy delivery to the contracting muscle. At the fuel substrate level, over 50% of the available glucose after a mixed-meal at rest will be stored as glycogen or oxidised by the skeletal muscles. Depending on exercise intensity the metabolic rate can increase up to 10-fold from the resting rate to meet the energy expenditure of the contracting muscle and most of energy is provided by the PDC-mediated CHO oxidation ([Fig. 2](#F2){ref-type="fig"}) \[[@B1]\].

In keeping with this observation, at the onset of submaximal muscle contraction (75% VO~2max~) PDCa raises rapidly, albeit at a slower rate than pyruvate formation, which may explain the initial muscle lactate accumulation, from resting values of around 0.3 to 0.5 (high value in trained subjects) to 2.0 to 3.0 (high value in trained subjects) mmol acetyl-CoA/min/kg wet muscle. Therefore, it is not unusual for muscle to oxidise 3 to 4 g of glucose per minute during the steady-state segment of a prolonged submaximal exercise \[[@B2]\].

In summary, it seems that maximal food-borne glucose disposal, especially oxidatively, would require optimisation of three interrelated responsive fundamentals: muscle mass, exercise, and a suitable activation of PDC.

REGULATION OF PDC ACTIVITY
==========================

PDC is a multicomplex mitochondrial enzyme, in fact the largest mammalian enzyme complex. PDC is composed of multiple copies of three catalytic (E1α/β-pyruvate dehydrogenase PDH, E2, and E3), one structural (E3-binding) and two regulatory proteins: PDH kinase (PDK) and PDH phosphatase (PDP). The enzyme complex is organised around a core consisting of component E2 to which E1 and E3 are joined by non-covalent bonds. Interaction of the three enzymes is brought about by lipoyl groups that visit sequentially the active sites on the three enzymes. The activation status of the PDC is controlled covalently via phosphorylation-dephosphorylation of three serine residues (Ser^232^, Ser^293^, Ser^300^) on the E1α subunit \[[@B3]\] by a competing kinase (PDK) and phosphatase (PDP) reactions \[[@B4]\]. The resulting interconversion cycle determines the amount of PDC existing in dephosphorylated or active form, i.e., PDCa \[[@B5]\]. When PDC is fully dephosphorylated the activity of PDC (maximal attainable for a given amount of protein) is labelled as total PDC (PDCt). Previous evidence from our laboratory has suggested that in humans there is a strong correlation between the amount of PDC protein and the whole body VO~2max~ \[[@B5]-[@B7]\]. In other words, trained subjects have a greater maximum capacity to oxidise CHO-derived-pyruvate than sedentary subjects. Although there is no apparent explanation for this observation at a first glance, it would appear that the protein level one of the catalytic components of PDC, (E1α/β-PDH), is increased when muscle specific peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) is overexpressed \[[@B8]\]. Since PGC-1α seems also to control mitochondrial biogenesis and VO~2max~ \[[@B9]\] then a link between PDCa and VO~2max~ can be made.

The PDK family comprises of four isoforms (PDK1 to 4) \[[@B10]\], whilst PDP has two isoforms (PDP1 to 2) \[[@B11]\]. Although PDK2 and PDK4 mRNA are expressed in most tissues, including skeletal muscle and heart, the specific activity of PDK4 is 8-fold greater than that of PDK2 \[[@B10]\], thereby assigning a greater regulatory significance to PDK4. PDK1 and PDK3 appear to be limited to heart, pancreatic islets and kidney \[[@B10]\]. Upon muscle stimulation following a nerve-initiated electrical impulse, calcium ions (Ca^2+^) are released from the sarcoplasmic reticulum, which surrounds each myofibril and floods the muscle cell, which then contracts. At the same time the mitochondrial Ca^2+^ uptake facilitates activation of PDP1, but not PDP2 \[[@B11]\], and thereby dephosphorylating/activating of muscle PDC ([Fig. 3](#F3){ref-type="fig"}).

Of particular importance to our understanding of how muscle PDCa is regulated during muscle contraction are the early findings from *in vitro* studies working with purified PDC isolated from kidney, heart, and skeletal muscle, which showed that increased levels of intracellular acetyl-CoA and NADH, the FFA oxidation end products, can inhibit PDCa either by activation of PDK4 activity, and thereby covalently reducing the amount of PDCa, or by allosterically inhibiting the activity of PDCa ([Fig. 3](#F3){ref-type="fig"}) \[[@B12],[@B13]\]. Nevertheless, it is worth noting here that in vivo experiments with high intensity involuntary contraction induced by percutaneous electrical stimulation in humans showed that regardless of the contraction-induced rise in the muscle acetyl-CoA/CoASH or NADH/NAD^+^ ratios a complete transformation or activation of muscle PDC to PDCa occurred \[[@B7]\]. A similar finding was observed during voluntary submaximal exhaustive exercise where the increased muscle acetyl-CoA/CoASH ratio during exercise did not cause inhibition of either the PDC activation or the calculated catalytic activity of active PDC \[[@B5]\]. Collectively, these *in vivo* data would suggest that following a standard mixed-meal (55% to 60% CHO, 30% to 35% fat, and 10% to 15% protein) the exercise mediated muscle acetyl-CoA and NADH accumulation do not inhibit the transformation/activation of PDC to PDCa. However, allosteric inhibition of flux through a given amount of PDCa does occur by limiting the mitochondrial NAD^+^ and CoASH availability \[[@B14],[@B15]\].

During muscle contraction the activation of PDC is achieved by the accumulation of mitochondrial calcium and pyruvate \[[@B16]\], which activate PDP1 and inhibit PDK2 and 4, respectively. Jointly, this ensures that CHO utilisation and activation of PDC increase in parallel with exercise intensity ([Table 1](#T1){ref-type="table"}) \[[@B5],[@B17]\].

Pertinent to type 2 diabetes (T2D), however, when exercise at submaximal workloads is preceded by several days of high-fat dietary intake, calcium and pyruvate seem unable to activate PDC to the same extent as in the control diet condition \[[@B18],[@B19]\], though they may at lower exercise intensities \[[@B20]\], resulting in reduced CHO oxidation compared to control at exercise intensities where muscle glycogen is an important contributor to energy production.

MUSCLE PDC ACTIVITY AND MUSCLE ACETYLCARNITINE ACCUMULATION
===========================================================

It would be inappropriate to discuss exercise and activity of PDC in contracting muscle without mentioning the significance of muscle acetylcarnitine accumulation. Studies in humans have demonstrated a decrease in muscle free carnitine levels, which was matched by an almost equivalent increase in acetylcarnitine during muscle contraction \[[@B6],[@B21]\]. These observed changes are consistent with the suggestion that carnitine, regulates the mitochondrial acetyl-CoA/CoASH ratio. By acting as an acceptor of acetyl groups from acetyl-CoA, carnitine may help to maintain a pool of free CoASH under conditions where the rate of acetyl-CoA condensation with oxaloacetate is less than its rate of formation from PDC mediated pyruvate decarboxylation. Thus, assuming that human muscle PDC was fully activated during exercise, it can be calculated that the rate of pyruvate decarboxylation to acetyl-CoA would be in excess of 30 µmol/sec/kg wet muscle \[[@B5]\]. If this rate of decarboxylation were supported solely by the CoASH available in muscle, i.e., 10 µmol/kg wet muscle \[[@B6]\], the entire pool of muscle CoASH would have been acetylated within one second of muscle contraction. Without the buffering effects of carnitine the PDC reaction and β-oxidation would be inhibited, since both reactions require a readily available pool of free CoASH ([Fig. 4](#F4){ref-type="fig"}). These findings have recently prompted research into a novel approach to treating the metabolic impairment in T2D by attempting to reduce the competition for CoASH between fat and CHO oxidation by increasing muscle carnitine pool \[[@B22]\].

PDC AND PDK4 IN HUMAN SKELETAL MUSCLE
=====================================

Activity of PDC in resting muscle appears to decline whenever muscle PDK4 expression is selectively up-regulated by its main physiological regulators, i.e., changes in FFA and insulin availability, in response to starvation, hormonal and substrate changes \[[@B23]-[@B25]\], in pathologies such as insulin resistance and T2D \[[@B26]-[@B28]\], inflammation \[[@B29],[@B30]\], or following medication with peroxisome proliferator-activated receptor (PPAR) agonists or statins \[[@B31],[@B32]\]. T2D related muscle metabolic inflexibility is often attributed to a low level of circulating inflammatory cytokines. Indeed, in a rodent model of lipopolysaccharide (LPS) induced endotoxemia we showed that a continuous infusion of LPS over 24 hours in conscious rodents increased extensor digitorum longus muscle PDK4 mRNA expression 24-fold, PDCa decreased by 65% lower and muscle lactate accumulation increased several-fold compared with the control (saline) \[[@B30]\]. These changes were preceded by early marked increases in muscle tumor necrosis factor-α and interleukin-6 mRNA expression. It was concluded that the elevation in muscle lactate concentration during LPS infusion is not attributable to limited muscle oxygen availability or adenosine triphosphate (ATP) production, but rather results from inhibition of muscle PDCa, most probably due to cytokine-mediated up-regulation of PDK4 transcription. Interestingly, in another similar rodent inflammatory model it was observed that concomitant with the up-regulation of skeletal muscle PDK4, there was also a down-regulation of the muscle Ca^2+^-dependent PDC phosphatase (PDP1) ([Fig. 5](#F5){ref-type="fig"}) \[[@B33]\].

In T2D and starvation, states which are well associated with high circulating FFA levels, PDP1 level in heart and presumably skeletal muscle is lower than in control \[[@B34]\]. It is pertinent therefore to suggest that a double setback (increased PDK4 and decreased PDP1) is imposed on the muscle PDCa in T2D patients. This may potentially account for the inability of mitochondrial Ca^2+^/pyruvate accumulation to fully activate human muscle PDC during single bouts of submaximal intensity cycling when they were preceded by short (3 days) \[[@B2],[@B19]\], or medium length (6 days) high fat dietary intake \[[@B35]\], when otherwise 10 minutes of exercise at 75% of VO~2max~, which was preceded by a normal Western diet should be sufficient to fully dephosphorylate/activate PDC \[[@B5]\].

Expression of the human PDK4 gene is increased in fasting and other conditions associated with a shift from glucose utilization to fatty acids as an energy provider. However, muscle PDK4 mRNA expression can be also increased under conditions of reduced muscle glycogen availability (exercise mediated), which the authors proposed to be attributable to glycogen regulatory enzymes such as protein phosphatase 1 and glycogen synthase kinase 3, which are bound to the glycogen structure only to be released when the glycogen level decreases \[[@B36]\]. The authors concluded that exercise-induced expression of metabolic genes may be co-ordinately linked to signalling mechanisms sensitive to glycogen level. However, this contention along with the proposed central role of pyruvate to muscle PDC activation in vivo may be overstated, at least during muscle contraction. Thus, the importance of glycogen availability and pyruvate formation to PDC activation during intense exercise in human skeletal muscle were investigated after glycogen depleting one-legged cycling exercise \[[@B16]\]. During a subsequent 10 minutes of two legged-exercise at 75% VO~2max~, it was clear that regardless of whether pre-exercise muscle glycogen content was at a typical resting concentration or depleted, the increase in PDC activation from its resting value was the same, despite pyruvate accumulation in the glycogen depleted leg during exercise being 3-fold lower than in normal glycogen leg. However, as a result of the reduction in pyruvate availability, calculated flux through PDC reaction was several-fold lower in the glycogen depleted state compared with normal. It is therefore pertinent to conclude that whilst muscle glycogen and pyruvate availability appear to be important to the rate of flux through PDC reaction during *in vivo* contraction, they are not of primary importance to the control of PDC activation under these conditions, which is probably principally regulated by muscle calcium availability.

INHIBITION OF MUSCLE PDC ACTIVITY BY DRUGS
==========================================

After medication with PPARs agonists and statins, which were prescribed in the diabetic population to improve blood lipidemic profile by increasing fat oxidation and reducing circulation cholesterol levels, unfortunately inhibition of muscle PDCa via increase in expression of muscle PDK4 mRNA and protein can also occur. By way of illustration, in a rodent model 6 days of medication with the PPAR-δ agonist GW610742 inhibited the activity of PDC-dependent CHO oxidation ([Fig. 6](#F6){ref-type="fig"}) \[[@B37]\] via up-regulation of PDK4 \[[@B31]\]. This impaired muscle function during a sustained contraction over 30 minutes where the demand on CHO use was markedly increased ([Fig. 7](#F7){ref-type="fig"}).

The importance of PDCa to the force development was also illustrated in a PDK4 knockout mice model whose extensor digitorum muscle was able to produce 40% more force than the corresponding muscle isolated from the wild type during high intensity electrically evoked contractions \[[@B38]\]. Since administration of PPAR agonists to humans and rodents has been linked to lower blood glucose levels, it seems therefore appropriate to suggest that any PPAR-δ mediated blood glucose lowering effect will be unlikely to be attributable to an increase in PDC-mediated oxidative glucose disposal as this route would be inhibited following PPAR-δ mediated inhibition of PDCa. Indeed, molecular and functional analyses suggest that PPAR-δ activation reduces blood glucose levels by reducing hepatic glucose output following increased glycolysis and the pentose phosphate shunt and promoting fatty acid synthesis in the liver \[[@B39]\].

Statins are the most prescribed class of drugs worldwide. Statins inhibit formation of mevalonate, and thereby the rate of hepatic cholesterol biosynthesis, by inhibiting 3-hydroxy-3-methyl glutaryl CoASH reductase. Therefore, statins are used clinically for blood cholesterol reduction in hypercholesterolaemia, and their use has been associated with a reduction in mortality in patient populations with pre-existing cardiovascular diseases \[[@B40]\]. However, treatment with simvastatin at 80 mg/kg body weight/day over 12 days in a rodent model up-regulated gene expression consistent with increased oxidative stress and inflammation in skeletal muscle \[[@B32]\]. Important to the present discussion, simvastatin markedly up-regulated muscle PDK2 and PDK4 mRNAs and glycogen level, which strongly suggests that muscle glycogen oxidation was impaired. Collectively, these findings indicate instauration of a muscle insulin resistance state after simvastatin treatment. Therefore, it may not be surprising that a recent meta-analysis of five human statin studies associated intensive high dose statin therapy with increased risk of new onset T2D \[[@B41]\]. The authors cautiously concluded that while the benefits of taking statins outweighs the negative effects there is a need to make patients aware of this possible risk and to monitor patients for development of diabetes, especially on intensive dose therapy.

MECHANISM OF PDK4 ACTIVATION BY PPARs/FOXO1
===========================================

Increases in circulating insulin level under normal dietary conditions, together with an increase in muscle Ca^2+^ availability during exercise appear to be the main physiological activators of muscle PDC in humans and they act by controlling the PDK4 and PDP1 activity, respectively. Activation of muscle PDC by insulin seems to occur via increased PDP1 and PDP2 activity following activation and translocation into mitochondria of the protein kinase Cδ \[[@B42]\].

Conditions with high circulating FFA levels as seen after a high-fat diet or in T2D, inflammation, PPAR agonist, or statin treatment are associated with an increase in muscle PDK4 mRNA and protein expression, thereby inhibiting activity of PDC at rest and during exercise. It has previously been suggested that activation of PPAR transcription factors (PPAR-α, -δ, -γ) by ligands, such as FFAs might be a mechanism responsible for the up-regulation of muscle PDK4 mRNA expression \[[@B31],[@B43]-[@B45]\]. Conversely, others have indicated that although PDK4 protein expression in an oxidative skeletal muscle is regulated by a lipid-dependent mechanism this is not obligatorily dependent on the PPAR-α signalling \[[@B46]\]. Secondly, the more rapid increase in PDK4 mRNA expression compared to PPAR-α mRNA expression following administration of a PPAR-α receptor agonist speaks against any involvement of PPARs in up-regulation of PDK4 \[[@B47]\]. Thirdly, a distinct association between levels of plasma FFA and levels of muscle PDK4 mRNA expression, together with a lack of any change in muscle PPAR-α mRNA or protein expression were documented during a 40 hours fast in humans \[[@B35]\]. Collectively, these data suggest other factors than PPARs could be responsible for the increase in PDK4 mRNA expression under conditions of increased circulating FFA availability.

Since FFAs can also indirectly induce the translocation of forkhead box (FOXO) transcription factors 1 and 3 to the nucleus \[[@B48],[@B49]\], and FOXO1 can bind directly to the promoter region of the PDK4 gene \[[@B48]\], it is reasonable to suggest that FOXO factors could also play an important role in promoting the up-regulation of PDK4 mRNA in response to increased FFA availability. Indeed, the FOXO family of transcription factors have been implicated in induction of muscle insulin resistance in vivo following the upstream dysregulation of insulin mediated stimulation of phosphoinositol 3-kinase and Akt1 \[[@B50],[@B51]\]. This is a pathway known to be sensitive to circulating insulin and FFA availability in humans \[[@B30]\]. Since FOXO1 can sense changes in availability of FFAs or insulin and relay the message downstream by modulating transcription of many skeletal muscle genes, including PDK4 \[[@B48],[@B50]\], it could inhibit the PDC controlled CHO oxidation ([Fig. 8](#F8){ref-type="fig"}).

While these findings were documented in in vitro or in animal models \[[@B48],[@B50]\], a recent study in humans in whom a muscle insulin resistant state was induced by consuming a high-fat diet for 3 days, has recognized FOXO1\'s involvement in up-regulation of muscle PDK4 mRNA and depression of muscle PDCa at rest and during a bout of 60 minutes of submaximal exercise \[[@B2]\]. Though PPAR-α mRNA was up-regulated by the high-fat diet, but to a smaller extent than PDK4 mRNA, the strong relationship between FOXO1 and PDK4 mRNA expression at rest and during exercise together with the less robust association between PPAR-α and PDK4 mRNA expression, support the notion that FOXO1 plays a more significant role than PPAR-α in the control of PDK4 expression and muscle CHO oxidation in insulin resistant state.

EFFECT OF DICHLOROACETATE ON PDC ACTIVITY AND CHO OXIDATION
===========================================================

Dichloroacetate (DCA) is a halogenated carboxylic acid that has been shown to increase the activity of PDC in animal \[[@B52]\] and human muscles \[[@B2],[@B53],[@B54]\] by competitively inhibiting PDK2 and PDK4 \[[@B10]\]. Several studies have demonstrated that DCA increases CHO oxidation, reduces muscle lactate accumulation simultaneously. Consistent with this, DCA has also been shown to lower blood glucose concentration in patients with T2D \[[@B55]\], probably due to increased muscle and liver oxidative glucose disposal \[[@B54],[@B56]\].

Although several studies using resting \[[@B54]\] or contracting human muscle \[[@B53]\] showed that DCA infusion resulted in increased resting muscle PDCa no study, until recently, has determined whether DCA administration at rest can offset the reported high-fat diet mediated PDK2 and PDK4 inhibition of PDC activation and CHO oxidation during subsequent exercise in humans \[[@B2]\].

A recent study has shown that indeed DCA administration is able to rescue the negative effects of 3-day of high-fat diet-mediated inhibition of muscle PDC activation both at rest and during subsequent exercise, and increased the rate of whole body CHO oxidation during exercise towards that seen in subjects receiving only an isocaloric control diet ([Fig. 9](#F9){ref-type="fig"}). The authors concluded these findings support the view that PDC plays a central role in the regulation of fuel selection and insulin resistance in muscle \[[@B2]\].

As discussed earlier in the present paper, administration of statins, especially at high doses, is associated with an increased prevalence of insulin resistance due to an up-regulation of muscle PDK4 isoform and decreased muscle PDCa, which collectively impair CHO oxidation. We were therefore interested to investigate whether administration of DCA could correct the impairment of CHO oxidation induced by simvastatin in a rodent model \[[@B57]\]. Compared with control, simvastatin (80 mg/kg/body weight) increased PDK4 protein expression and reduced muscle PDCa. However, when Simvastatin was administered with DCA (40 mg/kg/body weight) muscle PDK4 mRNA and protein were decreased while inhibition of muscle PDC activation was abolished.

Although DCA has proved once again to be an efficient oral antidiabetic agent that could reduce blood glucose and lactate by inhibiting hepatic glucose synthesis and stimulating glucose clearance \[[@B58]\] and use by peripheral tissues \[[@B59]\], including skeletal muscle, concerns about its lack of tissue specificity and long-term safety continue to hamper its therapeutic use as an antidiabetic agent.

DOES THE HYPOXIA-INDUCIBLE FACTOR-1α MEDIATED PDK4 UP-REGULATION MAKE CHUVASH POLYCYTHEMIA PATIENTS INSULIN RESISTANT?
======================================================================================================================

Hypoxia is a state that occurs in tissues when oxygen supplied by the cardiovascular system does not meet the demand for oxygen at cellular level. Tissue hypoxia occurs in normal physiological conditions such as contracting muscle as well as in pathophysiological settings such as inflammation \[[@B60]\], myocardial infarction and tumor formation \[[@B61]\]. In response to the low oxygen availability, the hypoxia-inducible factor (HIF) family of transcription factors are activated. One of them, HIF-1α, drives up-regulation of glycolytic enzymes to support an increase in glycolytic ATP production to bridge the decline in oxidative ATP production when mitochondrial oxygen availability is low. Experiments in cell culture have also identified a role for HIF-1α in down-regulating mitochondrial oxygen consumption by directly or indirectly inducing PDK1, which would inhibit PDCa \[[@B62]\]. However, these observations were restricted mainly to cell cultures or to a single PDK isoform (PDK1), and their significance for the intact organism remained largely unexplored. An opportunity to investigate the effects of altered HIF-1α levels in human skeletal muscle on all muscle PDK isoforms and PDCa was made possible by the condition of Chuvash polycythemia (CP), which is an autosomal recessive disorder with an endemic prevalence in the region of Chuvashia in the central European part of Russia. The CP patients have a mutation in the gene that controls for the von Hippel-Lindau (VHL) protein causing an arginine-to-tryptophan change at amino-acid residue 200 \[[@B63]\]. When bound to HIF-1α, the VHL protein allows complex recognition and subsequent destruction by the ubiquitin-proteasome proteolytic system. The change in VHL\'s primary amino acid structure impairs the interaction with HIF-1α, and thereby reduces the rate of HIF-α degradation and increases levels of HIF-downstream target genes under normoxic conditions. In a recent study, we measured metabolism after challenging the CP patients with a metabolic stress of exercise \[[@B64]\]. Exercise was a major metabolic stress for CP patients, since they had lower maximum exercise capacities and early muscle acidosis (lactate accumulation) compared with age- and gender sedentary-matched subjects. As expected for conditions characterised by high-level of HIF-1α, the skeletal muscle of the CP patients had elevated expression of glycolytic genes (i.e., hexokinase isoform 1 and 2, phosphofructokinase, M1 and M2 isoform of muscle pyruvate kinase, lactate dehydrogenase A). What was also novel was the evidence of a broad up-regulation of muscle PDK isoforms in the muscle of CP patients. Thus, three out four PDK isoforms (PDK1, 2, and 4) were markedly up-regulated compared with control. Of particular interest was PDK4 mRNA, which showed levels varying from 2- to 18-fold higher, compared to control. Recent evidence would suggest that the HIF-1α mediated up-regulation of PDK4 occurs via the orphan nuclear receptor estrogen related receptor γ \[[@B65]\]. Important to our understanding of why CP patients have lower exercise tolerance was the finding that the patients\' muscle have lower PDP1 levels and lower muscle PDCt compared with controls. Since CP patients have high muscle PDK4 levels and low PDCt activity, if consistent with our previous discussions, they should be insulin resistant. Nevertheless, their blood glucose is lower than controls \[[@B66]\]. A possible explanation for this inconsistency could be that HIF-1α also promotes decreased hepatic gluconeogenesis, increased skeletal muscle glucose uptake via increased expression of GLUT1 and increased glycolysis that all contribute to a systemic decrease in blood glucose concentrations \[[@B66]\].

CONCLUSIONS
===========

Activation of muscle PDC is the most important tool for oxidative glucose disposal. The increase in muscle acetyl-CoA and NADH, which is normally associated with exercise does not inhibit activation of muscle PDC, but can inhibit flux through PDC pathway.

Pyruvate availability is not important for activation of muscle PDC during exercise, but again it can limit the flux through PDC reaction. Calcium release appears to be the most important physiological activator of PDC during exercise.

Elevated muscle PDK4 induced by dietary fat intake or inflammation can blunt both activation and the flux through PDC reaction. Acute exercise can override to some extent the above inhibition, most likely via calcium release.

Since the response to insulin is blunted in T2D, the use of chronic/repetitive short concentric exercise (ideally high intensity training) \[[@B67]\], following close individual clinical control (tight monitoring of blood glucose level, the presence of silent heart ischaemia, presence of foot injuries, etc.) in combination with resistive exercise (to increase the muscle mass and therefore the whole body\'s ability to dispose glucose) can prove to be the norm for improving muscle insulin sensitivity ([Fig. 10](#F10){ref-type="fig"}). A short, but intensive exercise regimen, would also not allow the glucagon to further precipitate the rise in blood glucose levels following activation of glycogenolysis and gluconeogenesis in the liver. The exercise should take place early in the morning to coincide with the dawn phenomenon, i.e., the early rise in blood glucose level.

Alternatively, acute administration of DCA prior to exercise following several days of high-fat dietary intake can also fully activate muscle PDC and restore oxidative glucose use during exercise.
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![The competition between pyruvate dehydrogenase complex (PDC) activity-mediated carbohydrate oxidation and fat oxidation for the cellular coenzyme A (CoASH) and carnitine availability. NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide hydrogen; ATP, adenosine triphosphate; ADP, adenosine diphosphate; CPT, carnitine palmitoyl carnitine; TCA, tricarboxylic acid.](dmj-37-301-g004){#F4}

![(A) Muscle pyruvate dehydrogenase kinase isoform 4 (PDK4) and (B) pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) are concomitantly up- and down-regulated, respectively, in a lipopolysaccharide (LPS)-inflammation model compared with their corresponding control (saline). Adapted from Crossland et al. J Physiol 2008;586(Pt 22):5589-600 \[[@B33]\]. HMBS, hydroxymethylbilane synthase. ^a^Significantly different from control; *P*\<0.05.](dmj-37-301-g005){#F5}

![Muscle pyruvate dehydrogenase complex (PDC) activity at rest and after 30 minutes of electrically evoked submaximal intensity isometric contraction after 6 days of medication with different doses of peroxisome proliferator-activated receptor (PPAR)-δ agonist GW610742 (0 mg \[control; empty bar\], 5 mg \[grey bar\], and 100 mg kg^-1^ body weight \[black bar\]). Adapted from Constantin-Teodosiu et al. J Physiol 2009;587(Pt 1): 231-9 \[[@B37]\]. ^a,b^Significantly different from the corresponding control; *P*\<0.05.](dmj-37-301-g006){#F6}

![Rat skeletal muscle force during 30 minutes of electrically evoked submaximal intensity isometric contraction after 6 days of medication with different doses of peroxisome proliferator-activated receptor (PPAR)-δ agonist GW610742. Adapted from Constantin-Teodosiu et al. J Physiol 2009;587 (Pt 1):231-9 \[[@B37]\]. ^a^Significantly different from vehicle; *P*\<0.05.](dmj-37-301-g007){#F7}

![Mechanism of forkhead class O (FOXO) 1 mediated pyruvate dehydrogenase kinase isoform (PDK) 4 up-regulation and thereby pyruvate dehydrogenase complex (PDC)-mediated inhibition of carbohydrate oxidation. GLUT4, glucose transporter isoform 4; IGF, insulin-like growth factor; FFA, free fatty acid; TNF, tumor necrosis factor; PTEN, phosphatase and tensin homolog; PI3K, phosphoinositol 3-kinase; GSK, glycogen synthase; IRS-1, insulin receptor substrate 1.](dmj-37-301-g008){#F8}

![Human quadriceps muscle pyruvate dehydrogenase complex activity (PDCa) at rest, 10 and 60 minutes of submaximal intensity exercise (75% VO~2max~) with dichloroacetate (DCA) or saline infusion prior to exercise after 3 days of either a standard diet (CD) or high-fat diet (HFD). Adapted from Constantin-Teodosiu et al. Diabetes 2012;61:1017-24, with permission from American Diabetes Association \[[@B2]\].](dmj-37-301-g009){#F9}
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Metabolite levels in human skeletal muscle at rest and after 3×30 minutes bouts of exercise at 40%, 55%, and 75% of VO~2max~
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Values are presented as mean±standard deviation.

PDCa, pyruvate dehydrogenase complex activity.

^a^mmol/kg dry muscle, ^b^mmol/min/kg wet muscle.
